|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.430 HKD | -5.45% |
|
-8.30% | -46.48% |
Company Valuation: Cutia Therapeutics
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 3,030 | 2,120 | 1,482 | 763.4 | - | - |
| Change | - | -30.05% | -30.06% | -48.51% | - | - |
| Enterprise Value (EV) 1 | 2,471 | 2,055 | 1,469 | 832.1 | 763.4 | 601.7 |
| Change | - | -16.83% | -28.53% | -43.34% | -8.26% | -21.18% |
| P/E | -1.04x | -4.72x | -3.96x | -4.59x | 16.1x | 2.02x |
| PBR | 2.25x | 2.17x | 1.52x | 1.66x | 1.51x | 1.09x |
| PEG | -0x | 0.1x | 0.1x | 0.1x | -0x | 0x |
| Capitalization / Revenue | 22x | 7.58x | 4.41x | 1.18x | 0.65x | 0.44x |
| EV / Revenue | 18x | 7.35x | 4.37x | 1.29x | 0.65x | 0.35x |
| EV / EBITDA | -4.96x | -4.89x | -5.69x | -7x | 9.36x | 1.35x |
| EV / EBIT | -4.58x | -4.46x | -4.89x | -5.81x | 14.5x | 2.46x |
| EV / FCF | -5.65x | -4.38x | -4.87x | -2.71x | -27x | 9.76x |
| FCF Yield | -17.7% | -22.8% | -20.5% | -36.9% | -3.7% | 10.2% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -9.6 | -1.41 | -1.03 | -0.4581 | 0.1304 | 1.038 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 137.6 | 279.6 | 336.2 | 645.9 | 1,180 | 1,738 |
| EBITDA 1 | -498 | -419.9 | -257.9 | -118.8 | 81.56 | 444.6 |
| EBIT 1 | -538.9 | -461.1 | -300.1 | -143.3 | 52.79 | 244.1 |
| Net income 1 | -1,964 | -433.8 | -340.2 | -145.7 | 44.25 | 330.6 |
| Net Debt 1 | -559.6 | -64.73 | -13.8 | 68.7 | - | -161.7 |
| Reference price 2 | 9.967 | 6.653 | 4.080 | 2.101 | 2.101 | 2.101 |
| Nbr of stocks (in thousands) | 304,024 | 318,588 | 363,368 | 363,368 | - | - |
| Announcement Date | 27/03/24 | 24/03/25 | 24/03/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.59x | 1.29x | -7x | - | 113M | |
| 35.04x | 12.53x | 26.21x | 0.57% | 1,051B | |
| 27.19x | 6.2x | 16.98x | 2.12% | 609B | |
| 33.15x | 7.52x | 15.43x | 2.7% | 450B | |
| 17.85x | 4.43x | 10.91x | 3% | 330B | |
| 21.66x | 5.55x | 13.44x | 2.84% | 284B | |
| 21.16x | 4.46x | 12.34x | 1.97% | 263B | |
| 14.45x | 5.41x | 11.15x | 3.44% | 223B | |
| 24.02x | 6.35x | 11.22x | 2.75% | 198B | |
| -48.37x | 5.78x | 31.95x | 2.42% | 167B | |
| Average | 14.16x | 5.95x | 14.26x | 2.42% | 357.52B | |
| Weighted average by Cap. | 24.01x | 7.82x | 18.33x | 2% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 2487 Stock
- Valuation Cutia Therapeutics
Select your edition
All financial news and data tailored to specific country editions
